-
1
-
-
0028130605
-
The use of bisphosphonates in osteoporosis
-
Fleisch H. The use of bisphosphonates in osteoporosis. Br J Clin Pract. 1994;48:323-326.
-
(1994)
Br J Clin Pract
, vol.48
, pp. 323-326
-
-
Fleisch, H.1
-
2
-
-
0000192287
-
Bisphosphonates: Structural-activity relationships and therapeutic implications
-
Heersche JNM, Kanis J (eds.) Amsterdam: Elsevier
-
Geddes AD, D'Souza SM, Ebetino FH, Ibbotson KJ. Bisphosphonates: structural-activity relationships and therapeutic implications. Heersche JNM, Kanis J (eds.) In: Bone and Mineral Research/8. Amsterdam: Elsevier, 1995:265-306.
-
(1995)
Bone and Mineral Research/8
, pp. 265-306
-
-
Geddes, A.D.1
D'Souza, S.M.2
Ebetino, F.H.3
Ibbotson, K.J.4
-
4
-
-
0027378596
-
The role of bisphosphonates in the prevention and treatment of osteoporosis
-
Papapoulos SE. The role of bisphosphonates in the prevention and treatment of osteoporosis. Am J Med. 1993;95:48S-52S.
-
(1993)
Am J Med
, vol.95
-
-
Papapoulos, S.E.1
-
5
-
-
0027166137
-
Bisphosphonates in the treatment of metabolic bone diseases
-
Rodan GA, Balena R. Bisphosphonates in the treatment of metabolic bone diseases. Ann J Med. 1993;25:373-378.
-
(1993)
Ann J Med
, vol.25
, pp. 373-378
-
-
Rodan, G.A.1
Balena, R.2
-
6
-
-
0029055554
-
Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: Four-year randomized study
-
Wimalawansa SJ. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. Am J Med. 1995;99:36-42.
-
(1995)
Am J Med
, vol.99
, pp. 36-42
-
-
Wimalawansa, S.J.1
-
7
-
-
4243969763
-
Alendronate prevents bone loss at the spine and hip in recently postmenopausal women
-
Eisman JA, Christiansen C, McClung M, et al. Alendronate prevents bone loss at the spine and hip in recently postmenopausal women. J Bone Miner Res. 1995;10(suppl):S176.
-
(1995)
J Bone Miner Res
, vol.10
, Issue.SUPPL.
-
-
Eisman, J.A.1
Christiansen, C.2
McClung, M.3
-
8
-
-
0024847728
-
Prevention of postmenopausal bone loss by tiludronate
-
Reginster JY, Lecart MP, Deroisy R, et al. Prevention of postmenopausal bone loss by tiludronate. Lancet. 1989;ii:1469-1471.
-
(1989)
Lancet
, vol.2
, pp. 1469-1471
-
-
Reginster, J.Y.1
Lecart, M.P.2
Deroisy, R.3
-
9
-
-
0027529964
-
Bone density at various sites for prediction of hip fractures
-
Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. Lancet 1993;341:72-75.
-
(1993)
Lancet
, vol.341
, pp. 72-75
-
-
Cummings, S.R.1
Black, D.M.2
Nevitt, M.C.3
-
10
-
-
0024458249
-
Baseline measurement of bone mass predicts fracture in white women
-
Hui SL, Slemenda CW, Johnston CC. Baseline measurement of bone mass predicts fracture in white women. Ann Intern J Med. 1989;111:355-361.
-
(1989)
Ann Intern J Med
, vol.111
, pp. 355-361
-
-
Hui, S.L.1
Slemenda, C.W.2
Johnston, C.C.3
-
11
-
-
0027525577
-
Long-term fracture prediction by bone mineral assessed at different skeletal sites
-
Melton LJ, Atkinson EJ, O'Fallon WM, et al. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res. 1993;8:1227-1233.
-
(1993)
J Bone Miner Res
, vol.8
, pp. 1227-1233
-
-
Melton, L.J.1
Atkinson, E.J.2
O'Fallon, W.M.3
-
12
-
-
0023902418
-
Age and bone mass as predictors of fracture in prospective study
-
Hui SL, Slemenda CW, Johnston CC. Age and bone mass as predictors of fracture in prospective study. J Clin Invest. 1988;81:1804-1809.
-
(1988)
J Clin Invest
, vol.81
, pp. 1804-1809
-
-
Hui, S.L.1
Slemenda, C.W.2
Johnston, C.C.3
-
13
-
-
84970843849
-
Bone densitometry in clinical practise
-
Compston JE, Cooper C, Kanis JA. Bone densitometry in clinical practise. Br J Med J. 1995;310:1507-1510.
-
(1995)
Br J Med J
, vol.310
, pp. 1507-1510
-
-
Compston, J.E.1
Cooper, C.2
Kanis, J.A.3
-
14
-
-
0026232676
-
Bisphosphonates and vertebral fracture: An epidemiological perspective
-
Cooper C, Fogelman I, Melton LJ. Bisphosphonates and vertebral fracture: an epidemiological perspective. Osteoporosis Int. 1991;2:1-4.
-
(1991)
Osteoporosis Int
, vol.2
, pp. 1-4
-
-
Cooper, C.1
Fogelman, I.2
Melton, L.J.3
-
15
-
-
0025366467
-
Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis
-
Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. NEJM. 1990;322:1265-1271.
-
(1990)
NEJM
, vol.322
, pp. 1265-1271
-
-
Storm, T.1
Thamsborg, G.2
Steiniche, T.3
-
17
-
-
0026579492
-
Future prospects for hormone replacement therapy
-
Reeve J. Future prospects for hormone replacement therapy. Br J Med Bull. 1992;48:458-468.
-
(1992)
Br J Med Bull
, vol.48
, pp. 458-468
-
-
Reeve, J.1
-
18
-
-
0029131870
-
Estrogen therapy for postmenopausal symptoms and prevention of osteoporosis
-
Sagraves R. Estrogen therapy for postmenopausal symptoms and prevention of osteoporosis. J Clin Pharm. 1995;35:2-10.
-
(1995)
J Clin Pharm
, vol.35
, pp. 2-10
-
-
Sagraves, R.1
-
19
-
-
0028086440
-
Estrogen replacement therapy in older women: Comparisons between Alzheimer's disease cases and nondemented control subjects
-
Henderson VW, Paganini-Hill A, Emanuel CK, et al. Estrogen replacement therapy in older women: comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol. 1994;51:896-900.
-
(1994)
Arch Neurol
, vol.51
, pp. 896-900
-
-
Henderson, V.W.1
Paganini-Hill, A.2
Emanuel, C.K.3
-
20
-
-
0027266756
-
Hormone replacement therapy and risk of breast cancer: Results from epidemiologic studies
-
Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol. 1993;168:1473-1480.
-
(1993)
Am J Obstet Gynecol
, vol.168
, pp. 1473-1480
-
-
Colditz, G.A.1
Egan, K.M.2
Stampfer, M.J.3
-
21
-
-
0028568666
-
Major issues regarding estrogen replacement therapy in postmenopausal women
-
Bilezikian JP. Major issues regarding estrogen replacement therapy in postmenopausal women. J Women's Health. 1994;3:273-282.
-
(1994)
J Women's Health
, vol.3
, pp. 273-282
-
-
Bilezikian, J.P.1
-
22
-
-
0029071008
-
Hormone-replacement therapy - Breast versus heart versus bone
-
Davidson NE. Hormone-replacement therapy - breast versus heart versus bone. NEJM. 1995;332:1638-1639.
-
(1995)
NEJM
, vol.332
, pp. 1638-1639
-
-
Davidson, N.E.1
-
23
-
-
0030279060
-
Therapeutic controversy, estrogen replacement in menopause
-
Lindsay R, Bush TL, Grady D, et al. Therapeutic controversy, estrogen replacement in menopause. J Clin Endo & Met. 1996;81:3829-3838.
-
(1996)
J Clin Endo & Met
, vol.81
, pp. 3829-3838
-
-
Lindsay, R.1
Bush, T.L.2
Grady, D.3
-
25
-
-
0000122687
-
Changes in BMD substantially underestimate the anti-fracture effects of alendronate and other antiresorptive drugs
-
Cummings SR, Black DM, Vogt TM. Changes in BMD substantially underestimate the anti-fracture effects of alendronate and other antiresorptive drugs. J Bone Miner Res. 1996;11:Suppl 1:S102.
-
(1996)
J Bone Miner Res
, vol.11
, Issue.1 SUPPL.
-
-
Cummings, S.R.1
Black, D.M.2
Vogt, T.M.3
-
26
-
-
0026168474
-
Effect of cyclical therapy with phosphorus and etidronate on axial bone mineral density in postmenopausal osteoporotic women
-
Miller PD, Neal BJ, McIntyre DO, et al. Effect of cyclical therapy with phosphorus and etidronate on axial bone mineral density in postmenopausal osteoporotic women. Osteoporosis Int. 1991;1:171-176.
-
(1991)
Osteoporosis Int
, vol.1
, pp. 171-176
-
-
Miller, P.D.1
Neal, B.J.2
McIntyre, D.O.3
-
27
-
-
0028963682
-
Risk factors for hip fracture in white women. Study of osteoporotic fractures research group
-
Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of osteoporotic fractures research group. NEJM. 1995;767-773.
-
(1995)
NEJM
, pp. 767-773
-
-
Cummings, S.R.1
Nevitt, M.C.2
Browner, W.S.3
-
28
-
-
0026603713
-
Rates of change in bone mineral density of the spine, heel, femoral neck, and radius in healthy postmenopausal women
-
Harris S, Dawson-Hughes B. Rates of change in bone mineral density of the spine, heel, femoral neck, and radius in healthy postmenopausal women. Bone Miner. 1992;17:87-95.
-
(1992)
Bone Miner
, vol.17
, pp. 87-95
-
-
Harris, S.1
Dawson-Hughes, B.2
-
29
-
-
0029152138
-
Effect of menopause on femoral and vertebral bone loss
-
Pouilles JM, Tremollieres F, Ribot C. Effect of menopause on femoral and vertebral bone loss. J Bone Min Res. 1995;10:1531-1536.
-
(1995)
J Bone Min Res
, vol.10
, pp. 1531-1536
-
-
Pouilles, J.M.1
Tremollieres, F.2
Ribot, C.3
-
30
-
-
25744477916
-
Bone marker changes in etidronate or estrogen treated postmenopausal women are similar
-
Sacco-Gibson N, Lowry C, Smith J, et al. Bone marker changes in etidronate or estrogen treated postmenopausal women are similar. J Bone Miner Res. 1995;10(suppl):S351.
-
(1995)
J Bone Miner Res
, vol.10
, Issue.SUPPL.
-
-
Sacco-Gibson, N.1
Lowry, C.2
Smith, J.3
-
31
-
-
0028606037
-
Pamidronate: An unrecognized problem in gastrointestinal tolerability
-
Lufkin EG, Argueta R, Whitaker MD, et al. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporosis Int. 1994;4:320-322.
-
(1994)
Osteoporosis Int
, vol.4
, pp. 320-322
-
-
Lufkin, E.G.1
Argueta, R.2
Whitaker, M.D.3
-
32
-
-
0010496839
-
Esophagitis associated with the use of alendronate
-
De Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. NEJM. 1996;335:1016-1021.
-
(1996)
NEJM
, vol.335
, pp. 1016-1021
-
-
De Groen, P.C.1
Lubbe, D.F.2
Hirsch, L.J.3
-
33
-
-
0029840033
-
"Pill Esophagitis" - The case of alendronate
-
Castell DO. "Pill Esophagitis" - the case of alendronate. NEJM. 1996;335:1058-1059.
-
(1996)
NEJM
, vol.335
, pp. 1058-1059
-
-
Castell, D.O.1
|